The blood-brain barrier and methamphetamine: open sesame?

被引:41
作者
Turowski, Patric [1 ]
Kenny, Bridget-Ann [1 ]
机构
[1] UCL Inst Ophthalmol, Dept Cell Biol, 11-43 Bath St, London EC1V 9EL, England
关键词
methamphetamine; blood-brain barrier; endothelial cell; neurovascular unit; pinocytosis; tight junctions; neuroinflammation; CNS chemotherapy; EXPRESSION; TRANSPORTER; DISRUPTION; PERMEABILITY; PERICYTES; OCCLUDIN; NEUROINFLAMMATION; INTOXICATION; ACTIVATION; MICROGLIA;
D O I
10.3389/fnins.2015.00156
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The chemical and electrical microenvironment of neurons within the central nervous system is protected and segregated from the circulation by the vascular blood brain barrier. This barrier operates on the level of endothelial cells and includes regulatory crosstalk with neighboring pericytes, astrocytes, and neurons. Within this neurovascular unit, the endothelial cells form a formidable, highly regulated barrier through the presence of inter-endothelial tight junctions, the absence of fenestrations, and the almost complete absence of fluid-phase transcytosis. The potent psychostimulant drug methamphetamine transiently opens the vascular blood brain barrier through either or both the modulation of inter-endothelial junctions and the induction of fluid-phase transcytosis. Direct action of methamphetamine on the vascular endothelium induces acute opening of the blood-brain barrier. In addition, striatal effects of methamphetamine and resultant neuroinflammatory signaling can indirectly lead to chronic dysfunction of the blood-brain barrier. Breakdown of the blood-brain barrier may exacerbate the neuronal damage that occurs during methamphetamine abuse. However, this process also constitutes a rare example of agonist-induced breakdown of the blood-brain barrier and the adjunctive use of methamphetamine may present an opportunity to enhance delivery of chemotherapeutic agents to the underlying neural tissue.
引用
收藏
页数:7
相关论文
共 59 条
  • [1] Structure and function of the blood-brain barrier
    Abbott, N. Joan
    Patabendige, Adjanie A. K.
    Dolman, Diana E. M.
    Yusof, Siti R.
    Begley, David J.
    [J]. NEUROBIOLOGY OF DISEASE, 2010, 37 (01) : 13 - 25
  • [2] Disruption of central nervous system barriers in multiple sclerosis
    Alvarez, Jorge Ivan
    Cayrol, Romain
    Prat, Alexandre
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2011, 1812 (02): : 252 - 264
  • [3] Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease
    Argaw, Azeb Tadesse
    Asp, Linnea
    Zhang, Jingya
    Navrazhina, Kristina
    Trinh Pham
    Mariani, John N.
    Mahase, Sean
    Dutta, Dipankar J.
    Seto, Jeremy
    Kramer, Elisabeth G.
    Ferrara, Napoleone
    Sofroniew, Michael V.
    John, Gareth R.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (07) : 2454 - 2468
  • [4] Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
    Armulik, Annika
    Genove, Guillem
    Betsholtz, Christer
    [J]. DEVELOPMENTAL CELL, 2011, 21 (02) : 193 - 215
  • [5] Pericytes regulate the blood-brain barrier
    Armulik, Annika
    Genove, Guillem
    Mae, Maarja
    Nisancioglu, Maya H.
    Wallgard, Elisabet
    Niaudet, Colin
    He, Liqun
    Norlin, Jenny
    Lindblom, Per
    Strittmatter, Karin
    Johansson, Bengt R.
    Betsholtz, Christer
    [J]. NATURE, 2010, 468 (7323) : 557 - U231
  • [6] Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure
    Bowyer, John F.
    Robinson, Bonnie
    Ali, Syed
    Schmued, Larry C.
    [J]. SYNAPSE, 2008, 62 (03) : 193 - 204
  • [7] Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor
    Bunzow, JR
    Sonders, MS
    Arttamangkul, S
    Harrison, LM
    Zhang, G
    Quigley, DI
    Darland, T
    Suchland, KL
    Pasumamula, S
    Kennedy, JL
    Olson, SB
    Magenis, RE
    Amara, SG
    Grandy, DK
    [J]. MOLECULAR PHARMACOLOGY, 2001, 60 (06) : 1181 - 1188
  • [8] Capelôa T, 2014, NEUROTOX RES, V26, P216, DOI 10.1007/s12640-014-9464-1
  • [9] Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases
    Conant, K
    St Hillaire, C
    Anderson, C
    Galey, D
    Wang, J
    Nath, A
    [J]. JOURNAL OF NEUROVIROLOGY, 2004, 10 (01) : 21 - 28
  • [10] COOK CE, 1992, DRUG METAB DISPOS, V20, P856